UK markets closed
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • FTSE 250

    22,933.19
    +49.80 (+0.22%)
     
  • AIM

    1,233.68
    +1.14 (+0.09%)
     
  • GBP/EUR

    1.1710
    +0.0035 (+0.30%)
     
  • GBP/USD

    1.3820
    +0.0066 (+0.48%)
     
  • BTC-GBP

    27,152.38
    +2,019.75 (+8.04%)
     
  • CMC Crypto 200

    905.01
    -10.48 (-1.14%)
     
  • S&P 500

    4,422.30
    +10.51 (+0.24%)
     
  • DOW

    35,144.31
    +82.76 (+0.24%)
     
  • CRUDE OIL

    72.19
    +0.28 (+0.39%)
     
  • GOLD FUTURES

    1,797.40
    -1.80 (-0.10%)
     
  • NIKKEI 225

    27,833.29
    +285.29 (+1.04%)
     
  • HANG SENG

    26,192.32
    -1,129.66 (-4.13%)
     
  • DAX

    15,618.98
    -50.31 (-0.32%)
     
  • CAC 40

    6,578.60
    +9.78 (+0.15%)
     

Huntington’s Disease - Opportunity Assessment and Forecast to 2030

·4-min read

Summary Huntington’s disease (HD) is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired motor control, cognitive dysfunction, behavioral changes, and mood disorders.

New York, July 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Huntington’s Disease - Opportunity Assessment and Forecast to 2030" - https://www.reportlinker.com/p06105069/?utm_source=GNW
Depending upon the age of disease onset, HD can be classified into two forms: the more traditional adult-onset HD and the less prevalent juvenile-onset HD (JHD), also known as the Westphal variant of HD.

Approved treatments for HD across US, UK, and Germany are extremely limited, consisting of only two symptomatic treatments, tetrabenazine and deutetrabenazine, which are approved for the treatment of HD-associated chorea.Other treatment options contributing to the HD market are off-label off-patent symptomatic drugs including antipsychotics, antidepressants, benzodiazepines, anticonvulsants, antiparkinsonian drugs, and botulinum toxin.

To date, no disease-modifying drugs (DMDs) are available for the treatment of HD, and the current treatments are used in an attempt to alleviate the symptoms associated with this progressive disease.

Neurocrine’s Ingrezza (valbenazine) is expected to launch in the US in 2023, and it will directly compete with Teva’s Austedo (deutertabenazine).Huntexil (pridopidine) is expected to launch in 2025 in the US and in 2026 in Germany and the UK.

As it will target the non-choreic symptoms, it will likely be prescribed on top of other treatments, or it will replace some off-label drug use.

Key Highlights
- During the 10-year forecast period, there are two major pipeline products on track to launch, driving a forecast growth in the 3MM from $251.7m in 2020 to $917.7m in 2030.
- Neurocrine’s Ingrezza (valbenazine) is expected to launch in the US in 2023, and it will directly compete with Teva’s Austedo (deutertabenazine).
- Huntexil is expected to launch in 2025 in the US and in 2026 in Germany and the UK. As it will target the non-choreic symptoms, it will likely be prescribed on top of other treatments, or it will replace some off-label drug use.

Key Questions Answered
- What are the key HD treatments in 2020?
- When will the late stage pipeline products launch, and how will it affect drug sales and the overall HD market in the 3MM?
- Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope
- Overview of Huntington’s Disease, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline Huntington’s Disease market revenue from 2020-2030. Annual cost of treatment and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting Huntington’s Disease treatment sales in the 3MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global Huntington’s Disease market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Huntington’s Disease market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Huntington’s Disease market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06105069/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting